US/UK/Canada

Share

Contacts

  • Mark Waugh

    CEO


    +1 (260) 804-1342

    • Links

    Pick a time period -
    Tags ( Active)

    Performance of OssDsign Catalyst® in a patient with post-traumatic ankle arthritis showcased in medical journal

    Uppsala, Sweden, September 2, 2025. OssDsign AB (publ.) today announces that a case study of OssDsign Catalyst® as a bone void filler to augment total ankle arthroplasty in a patient with post-traumatic ankle arthritis has been published in the Biomedical Journal of Scientific & Technical Research.The rationale for the use of Catalyst Bone Graft for this patient, in addition to its ease of handling for the surgeon, was related to its mechanism of action, which includes both endochondral and intram­embranous ossification. The authors conclude that at three months follow up, CT scans show

    10,000 patients treated with OssDsign Catalyst® in the U.S.

    Uppsala, May 12, 2025. Today, OssDsign AB (publ.) announces that it has reached its milestone of 10,000 patients treated with the innovative nanosynthetic bone graft, OssDsign Catalyst, confirming its continued success in the U.S. orthobiologics market.The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021. ” With 10,000 patients treated, the adoption of OssDsign Catalyst is clearly accelerating. This is a substantial increase from the 5,000 patients reported in May

    Groundbreaking Study Highlights Enhanced Bone Formation with Novel Silicate-Containing Synthetic Bone Grafts

    Uppsala, April 11, 2025. OssDsign® AB (publ.) today announces that a new preclinical study comparing the bone-forming potential of different silicate-containing calcium phosphate synthetic bone grafts has been published in the peer-reviewed scientific journal Journal of Orthopaedic Surgery and Research. The study demonstrates that OssDsign Catalyst® is the first clinically available synthetic bone graft to successfully generate robust, functional bone in challenging avascular environments at early time points.A research team led by Professor Iain R. Gibson from the University of Aberdeen

    24-month follow up data from the clinical study of OssDsign Catalyst® show 100% spinal fusion

    Uppsala, April 9, 2025. OssDsign AB (publ.) today announces that the 24-month follow up results from the clinical study TOP FUSION will be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research. The results demonstrate a 100% spinal fusion rate and improved quality of life and pain after surgery with the innovative nanosynthetic bone graft OssDsign Catalyst.The data, soon to be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research, demonstrates that using OssDsign Catalyst leads to consistent and rapid bone

    OssDsign reaches its target of 300 patients enrolled in the prospective spinal fusion registry PROPEL

    Uppsala, February 25, 2025. OssDsign AB (publ.) today announced that the company has reached its target of 300 enrolled patients in the multi-center, prospective spinal fusion registry PROPEL. This registry, initiated in March 2022, collects real-world data from patients treated with OssDsign Catalyst."When we initiated the PROPEL registry, we communicated a target of 300 patients. Reaching this milestone already confirms our capability to gather clinically relevant data and the successful enrollment is a direct result of surgeons' high interest in collaborating with OssDsign to evaluate

    Withdrawal of proposed incentive programs and revised proposal on board composition and fees ahead of AGM in OssDsign

    The board of directors of OssDsign AB, following discussions with a larger group of major shareholders, announces the withdrawal of the proposed incentive programs and the nomination committee’s revised proposal as regards election of and fees payable to board members ahead of the annual general meeting.PRESS RELEASEOssDsign ABUppsala, 24 June, 2024  On 24 May 2024, the notice to OssDsign’s annual general meeting, to be held on 25 June 2024 in Stockholm, was published. In the notice, two (2) different share related incentive programs were proposed for employees and contractors and

    5,000 patients treated with OssDsign Catalyst® in the U.S.

    Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics market. To date, 5,000 patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst.The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021.   “With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it's accelerating. This is a significant leap from the earlier announcements of

    OssDsign Catalyst becomes universally available to all Military Treatment Facilities in the U.S. via ECAT

    OssDsign AB (publ.) today announces that the company’s nanosynthetic bone graft, OssDsign Catalyst has been included in the Department of Defense’s Military Health System’s electronic catalogue (ECAT), which means that the product is now universally available and can be ordered directly from any of the more than 50 Military Treatment Facilities in the U.S.The uptake of OssDsign Catalyst in ECAT has been mediated through the previously communicated collaboration with Red One Medical, a private-sector scout of medical innovation for the Department of Veterans Affairs (VA) and the Department

    OssDsign® Catalyst receives clearance from FDA for major new indication for use in interbody cages

    Uppsala, Sweden, September 18, 2023. OssDsign AB (publ.) today announces that the company’s innovative nanosynthetic bone graft OssDsign Catalyst has received clearance for use in interbody cages in spinal surgery from the U.S. Food and Drug Administration (FDA), allowing surgeons to use OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone.“This decision by the FDA represents one of the most important events in the history of

    2,000 patients treated with OssDsign® Catalyst in the U.S.

    Uppsala, September 13, 2023. OssDsign AB (publ.) today announces that the company’s orthobiologic business continues to accelerate its successful commercialization in the U.S. To this day, 2,000  patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst, up from 1,000 patients treated in May.With 2,000 patients treated, OssDsign Catalyst continues to show exponential growth from earlier records of 1,000 treated patients in May and 500 patients treated in January.   “It is great to see how our orthobiologics business continues its successful

    OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL

    Uppsala, August 16, 2023. OssDsign AB (publ.) today announces that the company has enrolled 200 patients in the multi-center, prospective spinal fusion registry, PROPEL. The registry was initiated in March 2022, to gather real-world data from patients who have been treated with OssDsign Catalyst."This important milestone reflects our ability to collect clinically relevant data and is a direct result of the high level of interest from surgeons to continue using OssDsign Catalyst, resulting in a growing number of patients being included in PROPEL. The collection of robust clinical evidence is

    1,000 patients treated with OssDsign® Catalyst in the U.S.

    Uppsala, May 9, 2023. OssDsign AB (publ.) today announces that 1,000 patients have been treated in the U.S. with the innovative nanosynthetic bone graft OssDsign Catalyst. Product awareness is increasing considerably, which is reflected in the rapidly growing number of patients treated.OssDsign Catalyst has been very well received in the U.S. market since its launch in August 2021. In January OssDsign reported that 500 patients had been treated since launch, and at the beginning of May the number increased to 1,000 patients.  “OssDsign Catalyst is growing exponentially driven by a

    OssDsign Catalyst 1cc is now launched and available in the U.S. market

    Uppsala, 10 January 2023. OssDsign AB (publ.) announces today that the company has now commenced the launch of a new size of OssDsign Catalyst in the U.S market. The additional volume option of 1 cubic centimeter (cc) is now fully available on the market and completes the existing product range of 10, 5 and 2,5 cc, thereby broadening the access to new procedures in both cervical spine and smaller extremities.“We are excited to announce that our new smaller size of OssDsign Catalyst is now available in the U.S. We see a rapidly growing interest in our innovative nanosynthetic bone graft, and

    OssDsign reaches milestone of 500 patients treated with OssDsign® Catalyst in the U.S.

    Uppsala, January 9, 2023. OssDsign AB (publ.) today announces that 500 patients have now been treated in the U.S. with the innovative nanosynthetic bone graft, OssDsign Catalyst. Since the launch, awareness of the product has increased exponentially, which is reflected in the growing number of patients who benefit from the treatment. Reaching the 500-patient milestone is a significant achievement in the effort to expand the product’s presence in the U.S. market.OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The

    First Post-Market Safety Report on OssDsign Catalyst shows zero percent device related complication rate

    Uppsala, November 17, 2022. OssDsign AB (publ.) today announces data from the first post-market safety report of the company's innovative product OssDsign Catalyst, that stimulates bone growth in spinal fusion. The report, which covers the time from product launch in August 2021 until August 31, 2022, did not record any device related complaints nor device related adverse events.OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. Similar to the body’s own bone mineral structure, the patented nanocrystalline

    OssDsign reaches milestone of 100 patients in its PROPEL registry ahead of time

    Uppsala, November 9, 2022. OssDsign AB (publ.) today announces that the company has reached the milestone of 100 patients in the multi-centre, prospective spinal fusion registry, PROPEL. The registry was initiated in March 2022, to gather real-world data from patients who have been treated with OssDsign Catalyst.During 2022, clinics have gradually enrolled patients to the PROPEL registry, with the objective to evaluate the use and outcome of OssDsign Catalyst in a real-world clinical practice. The primary endpoint of the study is measuring the rate of spinal fusion, using computer

    OssDsign extends the Catalyst portfolio and launches new product for additional surgical procedures

    Uppsala, 3 November 2022. OssDsign AB (publ.) announces today that the company is launching a new size of OssDsign Catalyst. The additional volume option of 1 cubic centimetre (cc) completes the existing product range of 10, 5 and 2,5 ccs, and broadens the access to new procedures in both cervical spine and smaller extremities. The product is expected to launch in the first quarter of 2023.The addition of the 1cc option completes the size range of OssDsign Catalyst, giving the company competitive strength in hospital approval processes and allowing for deeper usage in already approved

    The first 100 patients in the U.S. treated with OssDsign Catalyst

    Uppsala, June 13, 2022. OssDsign AB (publ.) today announces that the first 100 patients in the U.S. have now been treated with the company’s innovative synthetic bone graft OssDsign Catalyst. The product was launched in the U.S. market in August, 2021, and has since then been rapidly adopted by surgeons for use in spinal fusion surgeries. The achievement marks an important milestone as OssDsign continues to grow its commercial presence.OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a

    OssDsign announces that SEB has initiated research coverage of the company

    Uppsala, June 8, 2022. OssDsign AB (publ.) today announces that Skandinaviska Enskilda Banken (publ) (SEB) has been engaged to produce regular corporate research reports on the company. The intention is to raise the visibility of OssDsign in the capital market and enable investors as well as other stakeholders to develop an improved understanding of its business."We are glad to announce that SEB, one of the most well-renowned financial institutions in the Nordics, has initiated corporate research coverage in OssDsign. This will further increase our visibility in the financial community,"

    OssDsign announces the establishment of a U.S. Strategic Surgeon Advisory Board

    Uppsala, June 7, 2022. OssDsign AB (publ.) today announces that the company has established a Strategic Surgeon Advisory Board (SSAB) in the U.S. The primary objective of the SSAB is to assist the company with guidance and advice on strategic matters.The SSAB will consist of seven leading U.S. neurosurgical and orthopaedic spinal surgeons who will advise the company on matters related to the future direction and priorities for the company such as new product development, regulatory pathways, clinical programs and similar areas that carry strategic importance. OssDsign’s SSAB will

    OssDsign’s clinical study TOP FUSION is now fully enrolled

    Uppsala, April 25, 2022. OssDsign AB (publ.) today announces that the company’s clinical study TOP FUSION is fully enrolled and patient follow-up will continue to run over 24 months.The trial will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. The study’s primary endpoint will be assessed by the rate of bone fusion as well as a lack of device-related adverse events.   “We are very pleased to have completed the enrollment in this clinical trial and delivered on yet another major milestone. As TOP FUSION will provide key

    OssDsign enrolls the first patient to the multi-center prospective spinal fusion registry PROPEL in the U.S.

    Uppsala, April 4, 2022. OssDsign AB (publ.) today announces that the first patient has been enrolled to the company’s multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.The patient recruitment follows on the March 18 initiation of the first clinical site in PROPEL, a spinal fusion registry that initially will evaluate the rate of fusion, twelve months following treatment with the company’s nanosynthetic bone graft, OssDsign Catalyst. Additionally, the clinical safety

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media